Pelthos Therapeutics Inc. Accounts Payable and Accrued Liabilities, Fair Value Disclosure
Pelthos Therapeutics Inc. (PTHS) had Accounts Payable and Accrued Liabilities, Fair Value Disclosure of $8.28 thousand as of 2025-06-30, per its 10-Q filed 2025-08-13.
Financial Statements › Notes
us-gaap:AccountsPayableAndAccruedLiabilitiesFairValueDisclosure · last filed 2025-08-13
- 2025-06-30: Accounts Payable and Accrued Liabilities, Fair Value Disclosure $8.28K.
- 2025-03-31: Accounts Payable and Accrued Liabilities, Fair Value Disclosure $6.47K.
- 2024-12-31: Accounts Payable and Accrued Liabilities, Fair Value Disclosure $4.24K.
- 2024-09-30: Accounts Payable and Accrued Liabilities, Fair Value Disclosure $2.51K.
| Period end | Accounts Payable and Accrued Liabilities, Fair Value Disclosure |
|---|---|
| 2025-06-30 | $8.28K 10-Q · filed 2025-08-13 |
| 2025-03-31 | $6.47K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $4.24K 10-K · filed 2025-03-27 |
| 2024-09-30 | $2.51K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $895.00 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |